• Edesa Biotech entered an exclusive licensing agreement with KYORIN Pharmaceutical to develop and commercialize paridiprubart in Japan for acute respiratory distress syndrome.
• The deal provides a $12 million upfront payment, with potential development, regulatory and sales milestones of up to approximately $134 million.
• Tiered double-digit royalties on Japanese net sales are also payable under the agreement.
• Kyorin will fund development, regulatory and commercialization activities in Japan.
• Edesa retains all rights outside Japan and will manufacture and supply the product to Kyorin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090600PRIMZONEFULLFEED9873041) on November 09, 2026, and is solely responsible for the information contained therein.